Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 669-679

  Huisman, Christian ^a   Wisman, G Bea A ^a   Kazemier, Hinke G ^a   van Vugt, Marcel A T M ^a   van der Zee, Ate G J ^a   Schuuring, Ed ^a   Rots, Marianne G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Artificial Transcription Factors; Cellular responses to anticancer drugs; DNA methylation epigenetics; Methylation biomarkers; Novel antitumor agents; Tumor suppressor genes

Indexed keywords

ARTIFICIAL TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; GENE EXPRESSION; GENE FUSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VALIDATION PROCESS;

EID: 84878108856     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.017     Document Type: Article

References (50)

1. Bannister A.J., Miska E.A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. 2000, 57:1184-1192.
2. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
3. Beerli R.R., Dreier B., Barbas C.F. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. U.S.A 2000, 97:1495-1500.
4. Behrends C., Sowa M.E., Gygi S.P., Harper J.W. Network organization of the human autophagy system. Nature 2010, 466:68-76.
5. Beltran A., Parikh S., Liu Y., Cuevas B.D., Johnson G.L., Futscher B.W., Blancafort P. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 2007, 26:2791-2798.
6. Beltran A.S., Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 2011, 6:224-235.
7. Beltran A.S., Russo A., Lara H., Fan C., Lizardi P.M., Blancafort P. Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One 2011, 6:e24595.
8. Beltran A.S., Sun X., Lizardi P.M., Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol. Cancer. Ther. 2008, 7:1080-1090.
9. Boumber Y., Issa J.P. Epigenetics in cancer: what's the future?. Oncol. (Williston Park) 2011, 25:220-226. 228.
10. Cairns P., Esteller M., Herman J.G., et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 2001, 7:2727-2730.
11. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10:295-304.
12. de Groote M.L., Verschure P.J., Rots M.G. Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res. 2012, 40:10596-10613.
13. Edel M.J., Menchon C., Vaquero J.M., Izpisua Belmonte J.C. A protocol to assess cell cycle and apoptosis in human and mouse pluripotent cells. Cell. Commun. Signal 2011, 9:8.
14. Eijsink J.J., Lendvai A., Deregowski V., et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int. J. Cancer 2012, 130:1861-1869.
15. Eisenstein M. Sangamo's lead zinc-finger therapy flops in diabetic neuropathy. Nat. Biotechnol. 2012, 30:121-123.
16. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
17. Fukazawa T., Matsuoka J., Yamatsuji T., Maeda Y., Durbin M.L., Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int. J. Mol. Med. 2010, 25:3-10.
18. Gaj T., Guo J., Kato Y., Sirk S.J., Barbas C.F. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Meth. 2012, 9:805-807.
19. Glockner S.C., Dhir M., Yi J.M., et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009, 69:4691-4699.
20. Gommans W.M., McLaughlin P.M., Lindhout B.I., Segal D.J., Wiegman D.J., Haisma H.J., van der Zaal B.J., Rots M.G. Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol. Carcinog. 2007, 46:391-401.
21. Guan X., Stege J., Kim M., Dahmani Z., Fan N., Heifetz P., Barbas C.F., Briggs S.P. Heritable endogenous gene regulation in plants with designed polydactyl zinc finger transcription factors. Proc. Natl. Acad. Sci. U.S.A 2002, 99:13296-13301.
22. Hamada K., Alemany R., Zhang W.W., Hittelman W.N., Lotan R., Roth J.A., Mitchell M.F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996, 56:3047-3054.
23. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A 2003, 100:8933-8938.
24. Hoque M.O., Kim M.S., Ostrow K.L., et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res. 2008, 68:2661-2670.
25. Johung K., Goodwin E.C., DiMaio D. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J. Virol. 2007, 81:2102-2116.
26. Juergens R.A., Wrangle J., Vendetti F.P., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1:598-607.
27. Kaiser J. Epigenetic drugs take on cancer. Science 2010, 330:576-578.
28. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28:1069-1078.
29. Lara H., Wang Y., Beltran A.S., et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J. Biol. Chem. 2012, 287:29873-29886.
30. Liu P.Q., Rebar E.J., Zhang L., et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem. 2001, 276:11323-11334.
31. Lu Y., Zhang X., Zhang J. Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J. Cancer 2012, 3:333-344.
32. Lund C.V., Blancafort P., Popkov M., Barbas C.F. Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J. Mol. Biol. 2004, 340:599-613.
33. Magnenat L., Blancafort P., Barbas C.F. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J. Mol. Biol. 2004, 341:635-649.
34. Mandell J.G., Barbas C.F. Zinc finger tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res. 2006, 34:W516-W523.
35. Matei D.E., Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 2010, 116:195-201.
36. Ongenaert M., Wisman G.B., Volders H.H., Koning A.J., Zee A.G., van Criekinge W., Schuuring E. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med. Genomics 2008, 1:57.
37. Onori A., Desantis A., Buontempo S., Di Certo M.G., Fanciulli M., Salvatori L., Passananti C., Corbi N. The artificial 4-zinc-finger protein Bagly binds human utrophin promoter A at the endogenous chromosomal site and activates transcription. Biochem. Cell. Biol. 2007, 85:358-365.
38. Puigdecanet E., Espinet B., Lozano J.J., et al. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008, 22:1368-1376.
39. Raynal N.J., Si J., Taby R.F., Gharibyan V., Ahmed S., Jelinek J., Estecio M.R., Issa J.P. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res. 2012, 72:1170-1181.
40. Rius M., Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2012, 31:4257-4265.
41. Roossink F., de Jong S., Wisman G.B., van der Zee A.G., Schuuring E. DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. Cell. Oncol. (Dordr) 2012, 35:231-241.
42. Sera T. Zinc-finger-based artificial transcription factors and their applications. Adv. Drug Deliv. Rev. 2009, 61:513-526.
43. Snowden A.W., Zhang L., Urnov F., et al. Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res. 2003, 63:8968-8976.
44. Stolzenburg S., Rots M.G., Beltran A.S., Rivenbark A.G., Yuan X., Qian H., Strahl B.D., Blancafort P. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res. 2012, 40:6725-6740.
45. Uil T.G., Haisma H.J., Rots M.G. Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res. 2003, 31:6064-6078.
46. Wentzensen N., von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis. Markers 2007, 23:315-330.
47. Yang N., Eijsink J.J., Lendvai A., Volders H.H., Klip H., Buikema H.J., van Hemel B.M., Schuuring E., van der Zee A.G., Wisman G.B. Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3000-3007.
48. Yao Y.L., Yang W.M., Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol. Cell. Biol. 2001, 21:5979-5991.
49. Yu Y., Zeng P., Xiong J., Liu Z., Berger S.L., Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One 2010, 5:e12710.
50. Zhang B., Xiang S., Zhong Q., Yin Y., Gu L., Deng D. The p16-specific reactivation and inhibition of cell migration through demethylation of CpG islands by engineered transcription factors. Hum. Gene Ther. 2012, 23:1071-1081.